Clinical trials: Bacteremia Due to Staphylococcus Aureus
Staphylococcus Aureus Bacteremia
Identification and Validation of Clinical Phenotypes in Staphylococcus Aureus Bacteremia and Their Association With Mortality and Development of Complicated Bacteremia
The goal of this observational study is to determine retrospectively whether different patient clinical phenotypes (adults and children) develop Staphylococcus aureus bacteremia.The main questions it aims to answer qre: 1.
- Trial name
- FEN-AUREUS (NCT06574399)
- Where
- Spain
- Volunteers
- 1,000 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Staphylococcus Aureus
Chart Review of Outcome of Treatment for S. Aureus Bacteremia
The purpose of this study is to review medical records at MEDVAMC in order to relate the outcome of bacteremic MRSA infection to the antibiotics selected for treatment.
- Trial name
- NCT00304902
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Michael E. DeBakey VA Medical Center
Staphylococcus Aureus Bacteremia
Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia
The Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus aureus Bacteraemia (EVOS) study is a multicentre, randomized, open-label, parallel group, phase 3, non-inferiority trial of early intravenous to oral…
- Trial name
- EVOS (NCT06336824)
- Testing
- Tab. Trimethoprim-sulfamethoxazole, Tab. Clindamycin, Tab. Cephalexin, or Tab. Linezolid, IV Cloxacillin, IV Cefazolin, IV Vancomycin, or IV Ceftaroline
- Where
- 12 sites in Malaysia
- Volunteers
- 290 people
- Sponsor
- Clinical Research Centre, Malaysia
Staphylococcus Aureus Bacteremia
The Benefit of FDG PET CT in the Treatment Algorithm of Staphylococcus Aureus Bacteremia
Background: Staphylococcus aureus bacteremia (SAB) is frequently encountered in hospitals, with high rates of morbidity and mortality.
- Trial name
- PETCT4SAB (NCT02476487)
- Testing
- FDG PET CT
- Where
- Israel
- Volunteers
- 143 people
- Sponsor
- Rambam Health Care Campus
Staphylococcus Aureus Bacteraemia, Staphylococcal Bacteraemia
Comparison of Cloxacillin and Benzylpenicillin in Penicillin Susceptible S. Aureus Bacteraemia
The goal of this study is to investigate if benzylpenicillin is a better treatment option than cloxacillin in patients with penicillin-susceptible Staphylococcus aureus bacteraemia.
- Conditions
- Staphylococcus Aureus Bacteraemia, Staphylococcal Bacteraemia, Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia), Staphylococcus (S.) Aureus Infection
- Trial name
- COMeBAC (NCT06726395)
- Testing
- Penicillin G_1200mg, cloxacillin
- Where
- Sweden
- Volunteers
- 420 people
- Sponsor
- Region Skane
Immune Response To Sepsis, Staphylococcus Aureus Infection
Immune Resolution After Staphylococcus Aureus Bacteremia
The purpose of this study is to determine how monocyte HLA-DR and other markers of immune function change with time in patients with and without prior immune dysfunction who survive sepsis from Staphylococcus aureus bacteremia.
- Trial name
- NCT01879761
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- University of Chicago
Staphylococcus Aureus Bacteremia
Staphylococcus Aureus Bacteremia: Impact of an Intervention Program in Improving the Clinical Management and Review of the Clinical and Molecular Epidemiology
Staphylococcus aureus bacteremia: impact of an intervention program in improving the clinical management and review of the clinical and molecular epidemiology.
- Trial name
- NCT01971762
- Testing
- Follow recommendations based on scientific evidence to S. aureus bacteremia management, Not to follow recommendations based on scientific evidence to S. aureus bacteremia management
- Where
- 16 sites in Spain
- Volunteers
- 600 people
- Sponsor
- Fundación Pública Andaluza Progreso y Salud
Staphylococcus Aureus Bacteremia
Evaluating Simplified Layered Consent for Clinical Trials
The goal of this clinical trial (the SIMPLY-SNAP trial) is to compare a simplified layered consent form to a full-length consent form for use during the informed consent process for a larger clinical trial of treatment of…
- Trial name
- SIMPLY-SNAP (NCT06168474)
- Testing
- Simplified layered consent form, Full-length consent form
- Where
- 6 sites in Canada
- Volunteers
- 347 people
- Sponsor
- Sunnybrook Health Sciences Centre
Bacteremia
Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics
This is a Phase Ib, randomized double-blind, placebo-controlled multiple-ascending dose study to investigate the safety, tolerability, and pharmacokinetics of multiple doses of DSTA4637S when given in addition to…
- Trial name
- NCT03162250
- Testing
- DSTA4637S, SOC
- Where
- 16 sites in United States, South Korea and 1 more
- Volunteers
- 27 people
- Sponsor
- Genentech, Inc.
Staphylococcus Aureus, Bacteremia
Comparison of Nephrotoxicity and Hospital Costs in Patients With Methicillin-Resistant Staphylococcus Aureus Bacteremia Who Received Vancomycin Versus Teicoplanin Therapy
Staphylococcus aureus, the most virulent of the many staphylococcal species, has been recognized as one of the most important and lethal human bacterial pathogens.
- Trial name
- NCT01352936
- Where
- Taiwan
- Volunteers
- 190 people
- Sponsor
- Taipei Medical University WanFang Hospital
Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)
Linezolid Plus Standard of Care
The aim of the study is to assess whether targeting virulence factors by administering linezolid in addition to standard antibiotic treatment improves outcomes in patients with Staphylococcus aureus bacteraemia.
- Trial name
- LIPS (NCT06958835)
- Testing
- Linezolid 600 mg
- Where
- 12 sites in Switzerland
- Volunteers
- 606 people
- Sponsor
- University Hospital, Basel, Switzerland
Staphylococcus Aureus Bacteremia, Infective Endocarditis
Evaluation of the Usefulness of Echocardiography in Patients With Staphylococcus Aureus Bacteremia (ET-AUREUS Study).
The goal of this prospective interventionist cohort study is to assess the prevalence of infective endocarditis in patients with Staphylococcus aureus bacteremia at low risk of this complication.
- Trial name
- ET-AUREUS (NCT05862025)
- Testing
- Echocardiography evaluation
- Where
- Spain
- Volunteers
- 470 people
- Sponsor
- Puerta de Hierro University Hospital
Bacterial Endocarditis, Bacteremia
Daptomycin in the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to S. Aureus
The purpose of this study is to compare the safety and efficacy of daptomycin, an antibiotic, to standard therapy in subjects who have infective endocarditis or bacteremia due to Staphylococcus aureus (S. aureus).
- Trial name
- NCT00093067
- Testing
- daptomycin
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Staphylococcus Aureus Bacteremia
Early Infectious Disease Consultations in Staphylococcus Aureus Bacteremia
The primary objective is to determine if early infectious disease (ID) consultation (defined as within 48 hours of a positive blood culture) will reduce mortality rates from Staphylococcus aureus bacteremia (SAB).
- Trial name
- NCT00622882
- Testing
- infectious disease specialist consultation
- Where
- Singapore
- Volunteers
- 200 people
- Sponsor
- National University Hospital, Singapore
Staphylococcus Aureus Bacteraemia
Direct Thrombin Inhibitors Versus LMWH in Staphylococcus Aureus Bacteraemia
Safety and efficacy of direct thrombin inhibitors versus enoxaparin in patients with staphylococcus aureus bacteraemia. The study hypothesizes that inhibition of the coagulase-activity of S.
- Trial name
- NCT01911624
- Testing
- direct thrombin inhibition, enoxaparin
- Where
- Belgium
- Volunteers
- 94 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Staph Aureus Bacteremia
Optimizing the Management of Staphylococcus Aureus Bacteremia (OPTIMUS-SAB)
Staphylococcus aureus bacteremia (SAB) is associated with high morbidity and mortality rates with an incidence disproportionately higher in vulnerable populations.
- Trial name
- NCT06338176
- Testing
- OPTIMUS-SAB clinical care pathway
- Where
- 101 sites in Canada
- Volunteers
- 2,542 people
- Sponsor
- University of Alberta
Staphylococcus Aureus Bacteremia, Anti-Bacterial Agents
Phase IIa Clinical Study of N-Rephasin® SAL200
This study is performed to evaluate safety and to explore the efficacy of a single intravenous dose of N-Rephasin® SAL200 (3 mg/kg) in addition to the conventional standard treatment, for persistent Staphylococcus aureus…
- Trial name
- NCT03089697
- Testing
- N-Rephasin® SAL200
- Where
- 2 sites in South Korea
- Volunteers
- 25 people
- Sponsor
- Intron Biotechnology, Inc.
Bacteremia Due to Staphylococcus Aureus, Left Sided Infective Endocarditis (Disorder)
ERAdicate S. Aureus in Patients With Bacteremia and Endocarditis
This study evaluates safety and tolerability of endolysin-derived LSVT-1701 (tonabacase) as an add-on to standard of care (SOC) antibiotic therapy for the treatment of patients with complicated Staphylococcus aureus bacteremia…
- Conditions
- Bacteremia Due to Staphylococcus Aureus, Left Sided Infective Endocarditis (Disorder), Right Sided Infective Endocarditis (Disorder), Endocarditis Infective
- Trial name
- ERASE (NCT05329168)
- Testing
- Tonabacase (LSVT-1701)
- Where
- United States
- Sponsor
- Lysovant
Methicillin Susceptible Staphylococcus Aureus Septicemia, Bacteremia
Daptomycin as Adjunctive Therapy for Staphylococcus Aureus Bacteremia
The purpose of our study is to examine the effects of a second antibiotic, daptomycin, in combination with a beta lactam antibiotic on treating bloodstream infection caused by methicillin-susceptible S. aureus.
- Trial name
- DASH (NCT02972983)
- Testing
- Daptomycin
- Where
- Canada
- Volunteers
- 102 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Catheter Bacteremia, Staphylococcus Aureus Infection
Dalbavancin Versus Standard Antibiotic Therapy for Catheter-related Bloodstream Infections Due to Staphylococcus Aureus
The primary objective of the study is to demonstrate, among patients with non-complicated CR-BSIs due to S. aureus, that a single-dose of intravenous (IV) dalbavancin 1500 mg is non-inferior to standard documented antibiotic…
- Trial name
- DALICATH (NCT05117398)
- Testing
- Dalbavancin administration, Standard antibiotic therapy
- Where
- 2 sites in France
- Volunteers
- 406 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris